Ceribell Stock News

SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum...

CeriBell, Inc. ( CBLL ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Xingjuan Chao - Co-Founder, President, CEO & Director Scott Blumberg - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Josh...

SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025.

SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will ho...

Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies

CeriBell (CBLL) Q2 Revenue Jumps 38%

CeriBell, Inc. (NASDAQ:CBLL ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Scott Blumberg - Chief Financial Officer Xingjuan Chao - Co-Founder, President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Joshua Thomas Jennings -...

SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025.